Singapore markets closed

Straits Times Index
3,296.89
+4.20(+0.13%)
S&P 500
5,018.39
-17.30(-0.34%)
Dow
37,903.29
+87.37(+0.23%)
Nasdaq
15,605.48
-52.34(-0.33%)
Bitcoin USD
58,554.88
+779.60(+1.35%)
CMC Crypto 200
1,259.70
-11.05(-0.87%)

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD

Add to watchlist

0.5100

0.0000

(0.00%)

At close: 04:00PM EDT

Trade prices are not sourced from all markets

Press releases

Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
Business Wire
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO, August 23, 2023--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.